RSS-Feed abonnieren
DOI: 10.1055/a-1771-5985
Preclinical Safety Evaluation: Acute and Repeated-Dose Toxicity of a New Intranasal Recombinant Vector Vaccine TB/FLU-04L Against Tuberculosis
Funding This research was performed and funded as part of the scientific and technical program “Development of a vaccine against tuberculosis for public health of the Republic of Kazakhstan”.
Abstract
Background Vaccination against tuberculosis is one of the most successful medical measures to reduce morbidity and mortality. The BCG vaccine has been in use for more than 100 years, but its efficacy is still controversial. New vaccine candidates may offer better protection than available BCG vaccine. In this work, we studied the acute and the repeated-dose toxicity study of a new vector vaccine TB/Flu-04L against tuberculosis.
Materials and Methods The study was conducted on 60 BALB/c mice and 150 Wistar rats. The vaccine was administered intranasally and intravenously for the acute toxicity study. For the repeated-dose toxicity study, rats were intranasally immunized by 6.5 log10 TCID50 or 7.5 log10 TCID50 three times with 21-day intervals. Mortality, temperature, body weight, food and water consumption, hematological and biochemical parameters, urine analysis, as well as cardiovascular, respiratory, and central nervous system parameters were evaluated. A macroscopic examination of internal organs was performed.
Results The TB/FLU-04L vaccine did not cause death among the mice and rats in the acute toxicity study. There were no pathological abnormalities in animal condition, behavior, food and water consumption, temperature, and body weight during the observation period. The results suggest that intranasal repeated-dose administration of the TB/FLU-04L vaccine does not exhibit significant toxicity in rats.
Hematological and biochemistry analysis and the histological examination identified no toxicity-associated changes.
Conclusions The toxicity study in mice and rats showed that the intranasal vector vaccine TB/FLU-04L had no toxic effect. The tests confirm no adverse effects for laboratory animals in the studied parameters.
Publikationsverlauf
Eingereicht: 26. Januar 2022
Angenommen: 14. Februar 2022
Artikel online veröffentlicht:
06. April 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart,
Germany
-
References
- 1 Global tuberculosis report, 2020, WHO
- 2 Mirzayev F, Viney K, Linh NN. et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J 2021; 57: 2003300 DOI: 10.1183/13993003.03300-2020.
- 3 Abubakar I, Zignol M, Falzon D. et. al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect. Dis 2013; 13: 529-539 DOI: 10.1016/S1473-3099(13)70030-6.
- 4 Kaufmann SHE. Vaccination against tuberculosis: Revamping BCG by molecular genetics guided by immunology. Front Immunol 2020; 11: 316 DOI: 10.3389/fimmu.2020.00316.
- 5 Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11: S45-S53 DOI: 10.1038/nm1213.
- 6 Jeyanathan M, Yao Y, Afkhami S. et al. New tuberculosis vaccine strategies: taking aim at un-natural immunity. Trends Immunol 2018; 39: 419-433 DOI: 10.1016/j.it.2018.01.006..
- 7 Li J, Zhao A, Tang J. et al. Tuberculosis vaccine development: from classic to clinical candidates. Eur J Clin Microbiol Infect Dis 2020; 1: 21 DOI: 10.1007/s10096-020-03843-6.
- 8 Mironov AN, Bunatyan ND. A manual for conducting pre-clinical study of medicinal products. Part 2. Moscow: Grif I K Publishers; 2012: 536 pages In Russian